We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale.
To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity’s greatest challenges.
Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex™ valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success.
To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity’s greatest challenges.
Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex™ valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success.
Location: United States, California, San Carlos
Employees: 11-50
Total raised: $35M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | KdT Ventur... | kdtvc.com |
| - | Sahsen Ven... | sahsen.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.05.2024 | Series B | $35M | - |
Mentions in press and media 4
| Date | Title | Description |
| 15.05.2024 | Elegen Raises $35M in Series B Funding | Elegen, a San Carlos, CA-based company which specialises in DNA synthesis and production, raised $35M in Series B funding. The round was led by Triatomic Capital with participation from GSK and John Ballantyne, co-founder of Aldevron. Curre... |
| 10.01.2022 | New Year, New Fund, New Opportunities in Bio + Health | 2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both upstarts and tradit... |
| 15.09.2021 | Synthetic DNA healthtech helping the vaccine race secures $125m | From gene therapy and cancer treatments to next generation coronavirus vaccines, the world of genetic medicine is expanding at pace. Pivotal to the whole field is one thing: the availability of DNA. Touchlight, a London-based healthtech, ha... |
| - | Elegen | “Elegen is powering the bioeconomy with high-accuracy DNA synthesis that delivers industry-leading speed, length, and quality.” |